A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Overview

This is an open-label, multicenter, Phase 1/2 study to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D), and to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

SparkCures ID 1079
Trial Phase Phase 1/2
Enrollment 215 Patients
Treatments
Trial Sponsors
  • Celgene Corporation
NCT Identifier

NCT03989414

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  1. Subjects is ≥ 18 years of age and has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.
  2. Relapsed or refractory subjects must have measurable disease and have documented disease progression during or after their last anti-myeloma regimen.
  3. Newly diagnosed subjects must have documented diagnosis with previously untreated symptomatic multiple myeloma.
  4. Females of childbearing potential (FCBP) and male subjects must agree with the pregnancy prevention plan.

Exclusion Criteria:

  1. Subject has a significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  2. Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis.

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

Verified Winship Cancer Institute of Emory University
Verified John Theurer Cancer Center Hackensack Meridian Health

SparkCures Verified Accurate, up-to-date information. Learn more


Northwestern University Feinberg School of Medicine

Chicago, IL

Not Currently Accepting Patients

The following is a listing of trial locations that are not currently open and accepting patients.

Verified Wake Forest Baptist Comprehensive Cancer Center Wake Forest School of Medicine

SparkCures Verified Accurate, up-to-date information. Learn more


Mayo Clinic (Rochester)

Rochester, MN

Colorado
Florida
Georgia
Verified Winship Cancer Institute of Emory University

SparkCures Verified Accurate, up-to-date information. Learn more

Illinois
Northwestern University Feinberg School of Medicine

Chicago, IL

Massachusetts
Michigan
Minnesota
Mayo Clinic (Rochester)

Rochester, MN

New Jersey
Verified John Theurer Cancer Center Hackensack Meridian Health

SparkCures Verified Accurate, up-to-date information. Learn more

North Carolina
Verified Wake Forest Baptist Comprehensive Cancer Center Wake Forest School of Medicine

SparkCures Verified Accurate, up-to-date information. Learn more

Ohio
Tennessee
Texas
Washington

Resources

There are no resources, links or videos to display for this clinical trial.